Evotec 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Christian Wojczewski

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	1.6yrs
이사회 평균 재임 기간	2.9yrs

최근 관리 업데이트

Recent updates

CEO

Christian Wojczewski (52 yo)

less than a year

테뉴어

Dr. Christian Wojczewski serves as Chief Executive Officer of Evotec SE since July 01, 2024. He holds a diploma and a doctorate in chemistry from the Johann Wolfgang Goethe University in Frankfurt am Main....

리더십 팀

이름	위치	테뉴어	보상	소유권
Laetitia Rouxel	CFO & Member of Management Board	1.6yrs	€890.00k	0.029% CHF 418.5k
Cord Dohrmann	Chief Scientific Officer & Member of Management Board	14.2yrs	€1.48m	0.11% CHF 1.6m
Craig Johnstone	COO & Member of Management Board	5.8yrs	€1.18m	0.011% CHF 163.4k
Christian Wojczewski	Chief Executive Officer	less than a year	데이터 없음	데이터 없음
Aurelie Dalbiez	Chief People Officer & Member of Management Board	less than a year	데이터 없음	데이터 없음
Volker Braun	Executive VP and Head of Global Investor Relations & ESG	no data	데이터 없음	데이터 없음
Christian Dargel	EVP Global Head of Legal & Compliance	no data	데이터 없음	데이터 없음
Gabriele Hansen	Senior VP & Head of Global Corporate Communications & Marketing	no data	데이터 없음	데이터 없음
Ian Hunneyball	Senior Vice President of Programme Management & Clinical Operations	no data	€116.00k	데이터 없음
David Hallet	Executive Vice President	no data	데이터 없음	데이터 없음
Uwe Andag	EVP Head of Metabolic Diseases	no data	데이터 없음	데이터 없음
Christiane Honisch	SVP Head of Diagnostics	no data	데이터 없음	데이터 없음

1.6yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: EVT 의 관리팀은 경험 (평균 재직 기간 1.6 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Roland Sackers	Independent Vice Chairperson of the Supervisory Board	5.4yrs	€95.00k	데이터 없음
Iris Loew-Friedrich	Independent Chairperson of the Supervisory Board	10.4yrs	€150.00k	데이터 없음
Duncan McHale	Member of the Supervisory Board	less than a year	데이터 없음	데이터 없음
Camilla Languille	Member of the Supervisory Board	2.4yrs	€60.00k	데이터 없음
Constanze Ulmer-Eilfort	Independent Member of Supervisory Board	3.4yrs	€85.00k	데이터 없음
Wesley Wheeler	Independent Supervisory Board	less than a year	데이터 없음	데이터 없음

2.9yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: EVT 의 이사회는 경험(평균 재직 기간 2.9 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Evotec 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Evotec SE Announces Change in Management Board, Effective 01 October 2024

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Evotec SE, Annual General Meeting, Jun 10, 2024

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE Announces CEO Transition

Evotec SE, Annual General Meeting, Jun 20, 2023

Recent updates

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) made a non-binding expression of interest to acquire Evotec SE (XTRA:EVT) for €2 billion.

Triton Reportedly Weighs Takeover Deal for Drug Developer Evotec

Monacum Partners GmbH acquired Evotec Drug Substance (Germany) GmbH from Evotec SE (XTRA:EVT).

Evotec SE Announces Change in Management Board, Effective 01 October 2024

Second quarter 2024 earnings released: €0.54 loss per share (vs €0.084 loss in 2Q 2023)

Evotec SE Updates Earnings Guidance for the Fiscal Year 2024

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Evotec SE to Report Nine Months, 2024 Results on Nov 08, 2024

Evotec SE, Annual General Meeting, Jun 10, 2024

Evotec SE announced delayed 20-F filing

Full year 2023 earnings released: €0.47 loss per share (vs €0.99 loss in FY 2022)

Evotec SE Provides Earnings Guidance for the Year 2024

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE to Report Fiscal Year 2023 Results on Apr 24, 2024

Evotec SE to Report Q1, 2024 Results on May 22, 2024

Evotec SE Announces CEO Transition

Evotec SE Announces Zhejiang Jingxin Pharmaceutical Co., Ltd Receives Approval for EVT201 in China

Third quarter 2023 earnings released: €0.22 loss per share (vs €0.27 loss in 3Q 2022)

Evotec SE to Report Nine Months, 2023 Results on Nov 08, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: €0.084 loss per share (vs €0.16 loss in 2Q 2022)

Evotec SE (XTRA:EVT) acquired remaining 50% stake in NephTera Gmbh from Vifor (International) AG for €1.65 million.

Evotec SE Provides Revenue Guidance for the Full Year 2023

Evotec SE Revises Earnings Guidance for the Fiscal Year 2023

Evotec SE, Annual General Meeting, Jun 20, 2023

Full year 2022 earnings released: €0.99 loss per share (vs €1.30 profit in FY 2021)

Evotec SE Appoints Laetitia Rouxel as Member of the Management Board, Effective 01 April 2023

Evotec SE Reaffirms Earnings Guidance for the Full Year 2022

Evotec Launches PanOmics Data Analysis Platform PanHunter At Bio-IT World

Evotec SE (XTRA:EVT) agreed to acquire Central Glass Germany GmbH from Central Glass Co., Ltd. (TSE:4044) for €1.

Second quarter 2022 earnings released: €0.16 loss per share (vs €0.36 profit in 2Q 2021)

Evotec SE Revises Revenue Guidance for the Full Year 2022

Evotec SE (XTRA:EVT) completed the acquisition of Rigenerand S.R.L. from Xyence Capital SGR and others.

Evotec Se Appoints Camilla Macapili Languille as New Member of Supervisory Board

Evotec SE (XTRA:EVT) agreed to acquire Rigenerand S.R.L. for €25 million.

Evotec SE Confirms Revenue Guidance for 2022

Full year 2021 earnings released: EPS: €1.30 (vs €0.041 in FY 2020)

Full year 2021 earnings released: EPS: €1.30 (vs €0.041 in FY 2020)

Evotec Se Provides Revenue Guidance for 2022

Evotec SE Announces That the Company Has Been Informed by Bayer About A Decision to Discontinue the Development of the Investigational P2X3 Receptor Antagonist Eliapixant

Evotec SE to Report Q1, 2022 Results on May 11, 2022

Evotec Receives € 7.5 Million Grant for Development of Covid-19 Therapeutic from German Federal Ministry of Education and Research

Third quarter 2021 earnings released: EPS €0.82 (vs €0.009 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.36 (vs €0.065 loss in 2Q 2020)

Evotec SE Provides Revenue Guidance for the Full Year of 2021

Evotec SE (XTRA:EVT) acquired Campus Levi-Montalcini from GlaxoSmithKline plc (LSE:GSK).

Independent Chairman of Supervisory Board Wolfgang Plischke has left the company

First quarter 2021 earnings released: EPS €0.32 (vs €0.11 in 1Q 2020)

Evotec SE Reports Revenue Guidance for Revenue for the Full-Year 2021

Evotec SE Launches 'beLAB1407' to Accelerate Translational Research from the UK's Academic Life Science Ecosystem in Collaboration with Bristol Myers Squibb

Full year 2020 earnings released: EPS €0.041 (vs €0.25 in FY 2019)

Evotec SE Provides Earnings Guidance for the Year 2021

Chinook Therapeutics, Inc. and Evotec SE Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases

Evotec and Related Sciences Enter Integrated Drug Discovery and Development Partnership

Evotec SE Enters into Multi-Year Partnership with the Medical Center Hamburg-Eppendorf

Evotec Appoints Cord Dohrmann to the German Council of Science and Humanities

Evotec Starts Clinical Development of Chikungunya Antibody together with NIAID and Leading Academic Research Organisation

Evotec SE to Report Q3, 2021 Results on Nov 11, 2021

Evotec SE Receives USD 6 Million Payment from Bristol Myers Squibb Company

Evotec SE Partners with Alloy Therapeutics to Expand Its Antibody Discovery Platform

Evotec and Rappta Therapeutics Enter Discovery and Development Partnership Focused on Oncology Target

Revenue beats expectations

Third quarter 2020 earnings released: €0.009 loss per share

Evotec SE announced that it expects to receive €249.999996 million in funding from Mubadala Investment Company PJSC, Novo Holdings A/S

Evotec Achieves Milestone in Its Neurodegeneration Collaboration with Bristol Myers Squibb

Earnings released

CEO

테뉴어

리더십 팀